Liraglutide

Overview

What is Liraglutide and what does the research say?

Identity

Also Known As

Victoza • Saxenda • NN2211

Type

GLP-1 analog

Length

31 amino acids

Weight

3,751 Da

Sequence

HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG

Molecular Structure

H

A

E

G

T

F

T

S

D

V

S

S

Y

L

E

G

Q

A

A

K

E

F

I

A

W

L

V

K

G

R

G

Hydrophobic

Polar

Positive

Negative

Mechanism of Action

Liraglutide is an FDA-approved GLP-1 receptor agonist with extensive human clinical trial data. Its mechanisms are well-characterized through over 15 years of clinical use.

How It Works (Simplified)

Liraglutide mimics the natural incretin hormone GLP-1 with modifications that extend its action:

Scientific Pathways

GLP-1R/cAMP Pathway (Insulin Secretion)

Liraglutide binds GLP-1R → Gs protein activation → adenylyl cyclase → cAMP increase
                                                                        ↓
                                                      PKA activation → insulin exocytosis
                                                      (glucose-dependent)

Hypothalamic Pathway (Appetite Regulation)

Liraglutide → hypothalamic GLP-1R → POMC neuron activation → reduced food intake
                                  → NPY/AgRP inhibition → decreased hunger drive

Key Research: Marso SP et al. (LEADER Trial, 2016) demonstrated 13% reduction in major adverse cardiovascular events in high-risk T2D patients. PMID:27295427

Important Limitations

• Common GI side effects (nausea, vomiting) especially during titration
• Requires daily subcutaneous injection (less convenient than weekly alternatives)
• Boxed warning for thyroid C-cell tumors (based on rodent studies; human relevance uncertain)
• Contraindicated in personal/family history of medullary thyroid carcinoma or MEN2
• Weight regain typically occurs after discontinuation
• Less effective for weight loss than newer agents (semaglutide, tirzepatide)

Evidence-Chained Benefits

Evidence-Chained Benefits

Research findings linked to mechanisms and clinical outcomes

4 chains

Mechanism GLP-1 receptor activation on pancreatic beta cells stimulating glucose-dependent insulin secretion

Established 45 direct studies

Benefit shown to improve glycemic control in type 2 diabetes

Evidence Level

High

32 Human

8 Animal

5 In Vitro

View 2 key findings

RCT LEAD-6 Trial 2009 PMID:19564476

Liraglutide 1.8mg reduced HbA1c by 1.1% vs 0.8% for exenatide BID in T2D patients

RCT Vilsboll T et al. 2007 PMID:17383062

Demonstrated glucose-dependent insulin secretion mechanism minimizes hypoglycemia risk

Mechanism Activation of GLP-1 receptors in hypothalamus reducing appetite and increasing satiety signaling

Established 28 direct studies

Benefit shown to reduce body weight in obesity

Evidence Level

High

18 Human

6 Animal

4 In Vitro

View 2 key findings

RCT SCALE Obesity Trial 2015 PMID:25673378

Liraglutide 3.0mg achieved 8.0% weight loss vs 2.6% placebo at 56 weeks (N=3,731)

OBS Secher A et al. 2014 PMID:25169296

Confirmed CNS GLP-1R activation in appetite-regulating brain regions

Mechanism Multifactorial cardiovascular effects including blood pressure reduction and anti-inflammatory actions

Established 22 direct studies

Benefit shown to reduce cardiovascular events in high-risk T2D patients

Evidence Level

High

15 Human

5 Animal

2 In Vitro

View 2 key findings

RCT LEADER Trial 2016 PMID:27295427

13% reduction in MACE (CV death, MI, stroke) with HR 0.87 in 9,340 high-risk T2D patients

RCT Verma S et al. 2018 PMID:29122881

CV death benefit observed in heart failure subgroup from LEADER

Mechanism Delayed gastric emptying reducing postprandial glucose excursions

Established 12 direct studies

Benefit shown to reduce postprandial blood glucose spikes

Evidence Level

High

10 Human

2 Animal

View 2 key findings

RCT Harder H et al. 2004 PMID:18184924

Liraglutide significantly delays gastric emptying, contributing to glycemic control

RCT Flint A et al. 2008 PMID:18180765

Gastric emptying delay correlates with reduced food intake and enhanced satiety

Mechanism Confidence

Established

Supported

Emerging

Evidence Level

High

Moderate

Low

Very Low

What to Expect

Timeline based on observations from published studies. Individual responses may vary.

Week 1-2 PMID:17383062

Initial dose titration phase. Most patients experience transient nausea (25-40%) which typically improves. Early appetite suppression and reduced food intake begin. Blood glucose effects start within days.

Week 2-4 PMID:19171717

GI side effects diminish as tolerance develops. Weight loss becomes measurable (1-2 kg). HbA1c begins declining. Patients should reach target dose (1.8mg or 3.0mg) by end of this period.

Week 4-12 PMID:25673378

Steady weight loss continues. HbA1c reduction of 0.5-1.0% typically achieved. Full appetite suppression effects established. Most GI tolerability issues resolved.

Week 12-56 PMID:27295427

Maximum weight loss typically reached around weeks 40-56 (average 8% with 3.0mg dose). HbA1c maintained at 1.0-1.5% below baseline. Cardiovascular benefits emerge with longer-term use.

Research-Based Observations

This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.

Quality Checklist

Visual indicators to help evaluate Liraglutide product quality

Good Signs (6 indicators)

FDA-approved pharmaceutical product (Victoza or Saxenda)

Prescription obtained through licensed healthcare provider

Clear solution in pre-filled pen device

Proper storage at 2-8C before first use, room temperature after

Within expiration date with intact packaging

Manufacturer lot number traceable

Warning Signs (5 indicators)

Product not in original manufacturer packaging

Stored outside recommended temperature range

Obtained without valid prescription

Significantly below market price (potential counterfeit)

Approaching expiration date

Bad Signs (6 indicators)

Cloudy, discolored, or particulate-containing solution

Compounded or non-FDA-approved formulation

Frozen product (should never be frozen)

No manufacturer information or batch tracking

Purchased from unverified international sources

Damaged pen device or compromised seal

Positive quality indicator

Requires evaluation

Potential quality issue

For Research Evaluation Only

These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.

Peptide Interactions

Known and theoretical interactions when combining Liraglutide with other peptides. Based on published research and mechanistic considerations.

Synergistic

Compatible

Caution

Avoid

Ipamorelin

Compatible

Compatible

Different mechanisms (GLP-1 vs GHRP). Ipamorelin stimulates GH release while liraglutide affects glucose and satiety. No known direct interactions.

Tesamorelin

Compatible

Compatible

Tesamorelin is a GHRH analog targeting GH secretion. Different mechanism from liraglutide's GLP-1 agonism. Both may reduce visceral fat through different pathways.

BPC-157

Caution

Caution

Both affect GI function. BPC-157 is gastroprotective while liraglutide slows gastric emptying. Unclear if effects interact; monitor GI symptoms if combined.

Semaglutide

Avoid

Avoid

Both are GLP-1 receptor agonists. Concurrent use would result in overlapping mechanisms and increased risk of adverse effects including severe nausea, vomiting, and potential hypoglycemia. Never combine GLP-1RAs.

Tirzepatide

Avoid

Avoid

Tirzepatide is a dual GIP/GLP-1 agonist. Combining with liraglutide would cause receptor overstimulation, severe GI effects, and no additional therapeutic benefit. Choose one or the other.

Exenatide

Avoid

Avoid

Both are GLP-1 receptor agonists with overlapping mechanisms. Do not combine. Exenatide is shorter-acting but targets the same receptor pathway.

Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.

References

72 Sources

58 Human

14 Preclinical

Key Studies Cited

RCT LEAD-6 Trial 2009

PMID:19564476

RCT Vilsboll T et al. 2007

PMID:17383062

RCT SCALE Obesity Trial 2015

PMID:25673378

Human Secher A et al. 2014

PMID:25169296

RCT LEADER Trial 2016

PMID:27295427

RCT Verma S et al. 2018

PMID:29122881

RCT Harder H et al. 2004

PMID:18184924

RCT Flint A et al. 2008

PMID:18180765

Full reference list available on request. All citations link to PubMed for verification.

Methodology Note

This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.

For complete methodology details, see our Methodology page.